BenevolentAI is further evolving its differentiated technology platform and launching a new suite of products to capitalize on the vast potential of AI-driven technologies in the biopharma domain. Simultaneously, the Company is optimizing its portfolio to focus on its most advanced and promising pipeline assets. The new strategic plan: Maximizes the impact of BenevolentAI's innovative technology platform for commercial deployment through new revenue-generating products, collaborations, and partnerships. Prioritizes the Company's most advanced and high-potential clinical and pre-clinical assets, progressing them to their value inflection points.

Reduces spending and frees up £45 million of net cash to increase the Company's financial flexibility, extending the cash runway to at least July 2025 (without accounting for any new revenue).Aligns organizational structure to the new strategic direction. As part of the strategic plan, the Company will streamline and reorganize operations across two distinct business units - the Tech Business Unit and the Bio Business Unit - supported by Shared Business Operations.